Category: Eli Lilly
-
U.S. GLP-1 patent docket grows with raft of new complaints from Eli Lilly, Novo Nordisk
This could well be the start of a wide-ranging, multi-jurisdictional campaign by Eli Lilly to defend its rights around Mounjaro and Zepbound.
-
Federal Circuit revives Teva’s $177M (potentially $530M) damages verdict against Eli Lilly over Emgality headache drug
A $177M jury verdict, potentially tripled for willfulness, has been reinstated, and the standards for written description and enablement for genus-related patents have been clarified.